Objectives

After participating in this educational activity, attendees should be able to:

1. Understand the pathophysiology, epidemiology, and pathogenesis of opioid-induced constipation.
2. Compare current guideline recommendations and inpatient peripherally-acting mu-opioid receptor antagonist (PAMORA) efficacy/safety/budget impact.
3. Apply current guidelines and treatment evidence to patient examples.

Faculty

Matthew Murphy, PharmD
PGY1 Pharmacy Resident
Pharmacist
Baystate Medical Center

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education ( CE ) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options.  Faculty or planner conflicts of interest are resolved before the educational activity.

None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.